ArticleThe Journal of clinical endocrinology and metabolism2020
Decline Pattern of Beta-cell Function in Adult-onset Latent Autoimmune Diabetes: an 8-year Prospective Study.
Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.Signal transduction and targeted therapy · 2023Trial
- C-peptide in Precision Diabetes Care and Beyond: A Comprehensive Review.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- An Adult Case of Diabetes With High Levels of GAD Antibodies Without Insulin Deficiency for More Than 10 Years.Case reports in endocrinology · 2025Article
- Atypical Diabetes: What Have We Learned and What Does the Future Hold?Diabetes care · 2024Review
- Utility of Fasting C-Peptide for the Diagnostic Differentiation of Patients with Type 1, Type 2 Diabetes, MODY, and LADA.Life (Basel, Switzerland) · 2024Article
- GAD65Abs Are Not Associated With Beta-Cell Dysfunction in Patients With T2D in the GRADE Study.Journal of the Endocrine Society · 2024 · on this mapArticle
- Differential Associations of GAD Antibodies (GADA) and C-Peptide With Insulin Initiation, Glycemic Responses, and Severe Hypoglycemia in Patients Diagnosed With Type 2 Diabetes.Diabetes care · 2023Article
- C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.Diabetes, obesity & metabolism · 2022Review
- Rapid Point-of-Care Test for Determination of C-Peptide Levels.Journal of diabetes science and technology · 2022Article
- Islet Autoimmunity is Highly Prevalent and Associated With Diminished β-Cell Function in Patients With Type 2 Diabetes in the Grade Study.Diabetes · 2022 · on this mapArticle
- Latent autoimmune diabetes in adults: a focus on β-cell protection and therapy.Frontiers in endocrinology · 2022Review
- Innate immunity in latent autoimmune diabetes in adults.Diabetes/metabolism research and reviews · 2022Review
- Latent autoimmune diabetes in adults in China.Frontiers in immunology · 2022Review
- A clinical diagnostic model based on an eXtreme Gradient Boosting algorithm to distinguish type 1 diabetes.Annals of translational medicine · 2021Article
- Latent Autoimmune Diabetes in Adults (LADA) and its Metabolic Characteristics among Yemeni Type 2 Diabetes Mellitus Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.Diabetes · 2020Article
- Decline Pattern of Beta Cell Function in LADA: Relationship to GAD Autoantibodies.The Journal of clinical endocrinology and metabolism · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the decline pattern and possible determinants of beta-cell function progression in patients with latent-onset autoimmune diabetes in adults (LADA). RESEARCH DESIGN AND
methodsIn this 8-year prospective study, 106 LADA individuals underwent annual follow-up and their pattern of beta-cell function progression was assessed. Beta-cell function failure was defined by fasting C-peptide (FCP) < 75 pmol/L. Other clinical characteristics, including age of onset, body mass index (BMI), and glutamic acid decarboxylase autoantibody (GADA) titer, were analyzed to find out possible determinants of beta-cell function progression.
resultsThe dropout rate was 4.7%. During the 8-year follow-up period, 29 (28.7%) of the 101 subjects developed beta-cell function failure. The decline pattern of C-peptide in LADA was biphasic, showing an initial rapid linear progression and then followed by a stable mode. The declination speed of FCP was 55.19 pmol/L/year (95% CI, -62.54 to -47.84, P < 0.001) during the first 5 years and 4.62 pmol/L/year (95% CI, -69.83 to 60.60, P = 0.790) thereafter. Further analysis showed that GADA titer was the most valuable discriminatory parameter related to a higher risk of development of beta-cell function failure (GADA titer of 173.5 WHO units/mL; area under the curve [AUC], 0.824). Beta-cell function failure occurred in 71.3% of high-GADA titer patients while only 6.2% of low-titer patients.
conclusionsThe decline pattern of C-peptide was a fast-followed-by-slow biphasic mode, with about a quarter of LADA patients developing beta-cell function failure during the first 8 years. GADA titer less than 173.5 WHO units /mL was propitious for the preservation of beta-cell function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.